Novo Nordisk

When Danish pharmaceutical giant Novo Nordisk introduced Ozempic, it was more than just a breakthrough—it was a testament to their motto: “Driving Change Across Generations.”

This injectable has transformed the lives of millions battling uncontrolled diabetes, delivering unprecedented effectiveness.

The secret? It not only controls blood sugar but also drives weight loss, tackling two interconnected challenges—diabetes and obesity—that fuel each other in a vicious cycle.

But in India—the diabetes capital of the world—patients prefer pills over injectables. Novo Nordisk understood this and took innovation a step further.

Enter Rybelsus—the world’s first oral semaglutide. A game-changer designed primarily for Indian patients, offering the same powerful benefits as its injectable counterpart, but in a pill.

For countless Indians, Rybelsus has been a second chance at life. A beacon of hope for those who felt like every day was an uphill battle.

We set out to capture the raw emotions and powerful transformations of these patients.

Meet Kalpana.

Her journey with Rybelsus is heartwarming, uplifting, and a testament to the power of medical innovation.